- Generative protein design model research
- Concentrates on drug discovery depth over broad coverage
- Scales to organization-wide research rollouts
Latent Labs
Generative protein design model research
SF6.9
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Identify drug targets from biology dataProtein design and biotech researchers
Identify drug targets from biology dataProtein design and biotech researchers
Best for
Protein design and biotech researchers
Pricing
Custom
SoftFinders Score
6.9 / 10
Overview
What is Latent Labs?
Latent Labs is an AI biology company building generative protein design models for biotech researchers working on programmable biology and drug discovery.
- Research focus: The product centers on R&D acceleration and computational biology rather than guaranteed clinical outcomes.
- Buyer fit: Its clearest fit is protein design and biotech researchers seeking generative protein design model research.
- Engagement model: Work typically happens through pharma partnerships rather than self-serve subscription buying, so buyers should weigh data access, timelines to validated leads, and collaboration costs.
- Commercial consideration: Latent Labs is early-stage and research-facing today, while pricing is sales-led and scoped per buyer rather than posted publicly.
A small pilot can confirm workflow fit and downstream validation requirements before teams commit to a wider discovery rollout.
KEY FEATURES
What you get out of the box
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Coordinates pharma partner collaboration workflows
Target Discovery
Identifies potential drug targets from biological data
Molecule Design
Generates and ranks small molecule candidates
USE CASES
Where teams put it to work
Identify drug targets from biology data
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Editorial Take
What we like, and what to verify
- Early-stage and research-focused in most deployments today
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ